Literature DB >> 20232106

Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma.

Toni Valković1, Antica Duletić-Načinović, Sanja Stifter, Milena Hasan, Ita Hadžisejdić, David Zombori, Blaženka Grahovac, Nives Jonjić.   

Abstract

Non-Hodgkin lymphoma (NHL) is one of the most common malignancies whose incidence increases, and the treatment results are not satisfactory. The aim of this study was to determine the capacity of NHL to produce MCP-1, chemokine that induces chemotaxis of macrophages and lymphoid cells. The mRNA expression and protein MCP-1 expression were determined in the samples of 20 patients with NHL and 8 reactive tonsils. MCP-1 mRNA was detected in 8/8 tonsils and in 19/20 patients with NHL by real-time PCR analysis. In addition, the amount of detected MCP-1 cDNA was significantly higher in patients with limited stage, good IPI, normal level of fibrinogen and LDH. Finally, in patients with aggressive NHL, the level of MCP-1 cDNA was higher than in indolent tumours. Immunohistochemical analysis revealed that majority of stromal elements such as macrophages, endothelial and smooth muscle cells in reactive as well as in neoplastic lymphoid tissue showed strong cytoplasmic MCP-1 expression. Moderate cytoplasmic MCP-1 expression was also observed in reactive lymphocytes, while tumour cells of indolent NHL were mostly pale in comparison with aggressive lymphomas which predominantly demonstrated intense MCP-1 staining. These intriguing preliminary results emphasize the need for further investigations that must be conducted on the representative sample with concordant measurement of serum MCP-1 level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20232106     DOI: 10.1007/s10238-010-0093-6

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  29 in total

1.  The monocyte chemotactic protein a (MCP-1) and interleukin 8 (IL-8) in Hodgkin's disease and in solid tumours.

Authors:  M G Luciani; A Stoppacciaro; G Peri; A Mantovani; L P Ruco
Journal:  Mol Pathol       Date:  1998-10

Review 2.  Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma.

Authors:  Antonio J Grillo-López
Journal:  Expert Rev Anticancer Ther       Date:  2002-10       Impact factor: 4.512

Review 3.  Location, movement and survival: the role of chemokines in haematopoiesis and malignancy.

Authors:  Arian D J Laurence
Journal:  Br J Haematol       Date:  2006-02       Impact factor: 6.998

4.  Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma.

Authors:  H A Preti; F Cabanillas; M Talpaz; S L Tucker; J F Seymour; R Kurzrock
Journal:  Ann Intern Med       Date:  1997-08-01       Impact factor: 25.391

Review 5.  Cytokine deregulation in cancer.

Authors:  R Kurzrock
Journal:  Biomed Pharmacother       Date:  2001-11       Impact factor: 6.529

6.  Inhibition of the angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide.

Authors:  Mee Young Kim; Cheol Woo Byeon; Kyung Hee Hong; Ki Hoon Han; Sunjoo Jeong
Journal:  FEBS Lett       Date:  2005-03-14       Impact factor: 4.124

7.  Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas.

Authors:  Livio Trentin; Anna Cabrelle; Monica Facco; Davide Carollo; Marta Miorin; Alicia Tosoni; Paola Pizzo; Gianni Binotto; Linda Nicolardi; Renato Zambello; Fausto Adami; Carlo Agostini; Gianpietro Semenzato
Journal:  Blood       Date:  2004-03-04       Impact factor: 22.113

8.  International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades.

Authors:  J Hermans; A D Krol; K van Groningen; P M Kluin; J C Kluin-Nelemans; M H Kramer; E M Noordijk; F Ong; P W Wijermans
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

9.  Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1.

Authors:  Karin Jöhrer; Katrin Janke; Jens Krugmann; Michael Fiegl; Richard Greil
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

Review 10.  Progress and promise in the treatment of indolent lymphomas.

Authors:  Peter McLaughlin
Journal:  Oncologist       Date:  2002
View more
  2 in total

1.  Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.

Authors:  F Pauly; K Fjordén; S Leppä; H Holte; M Björkholm; Ø Fluge; L Møller Pedersen; M Eriksson; A Isinger-Ekstrand; C A K Borrebaeck; M Jerkeman; C Wingren
Journal:  Blood Cancer J       Date:  2016-11-18       Impact factor: 11.037

Review 2.  Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?

Authors:  Hiroaki Iwamoto; Kouji Izumi; Atsushi Mizokami
Journal:  Int J Mol Sci       Date:  2020-12-07       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.